Literature DB >> 10932459

Effect of patient information on the quality of pharmacists' drug use review decisions.

T Warholak-Juarez1, M T Rupp, T A Salazar, S Foster.   

Abstract

OBJECTIVE: To evaluate the effect of incremental increases in patient information on the quality of pharmacists' clinical decisions related to legally mandated prospective drug utilization review (DUR) responsibilities.
DESIGN: Unblinded comparison of two groups. PARTICIPANTS: 28 community pharmacists in Indiana (group 1) and 32 Public Health Service pharmacists employed in the Indian Health Service (IHS) (group 2).
INTERVENTIONS: Clinical cases involving prescribing problems were developed from patient charts. Each case contained four levels of increasing patient information: Level 1 included only information required for a legal prescription in Indiana; Level 2 added the patient's current medication profile, age, and allergies; Level 3 added the diagnosis or reason for use of the prescribed medication; and Level 4 added the physician's progress note. Pharmacists were asked to evaluate the prescribed drug therapy at each level of each case and complete a Dispensing Appropriateness Index (DAI) report, which included all prospective DUR criteria required by the Omnibus Budget Reconciliation Act of 1990. The quality of pharmacists' DUR decisions at each level of patient information was evaluated by comparing pharmacists' responses on the DAI reports with the consensus judgment of two clinical experts.
RESULTS: The quality of both community and IHS pharmacists' DUR decisions improved significantly at each incremental level of patient information.
CONCLUSION: Pharmacists in this study made better decisions when they had access to more complete patient information on which to base their decisions.

Entities:  

Mesh:

Year:  2000        PMID: 10932459

Source DB:  PubMed          Journal:  J Am Pharm Assoc (Wash)        ISSN: 1086-5802


  8 in total

1.  Medication error identification rates by pharmacy, medical, and nursing students.

Authors:  Terri L Warholak; Caryn Queiruga; Rebecca Roush; Hanna Phan
Journal:  Am J Pharm Educ       Date:  2011-03-10       Impact factor: 2.047

Review 2.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 3.  Repeat prescribing: scale, problems and quality management in ambulatory care patients.

Authors:  Peter A G M De Smet; Maaike Dautzenberg
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  What do Australian consumers, pharmacists and prescribers think about documenting indications on prescriptions and dispensed medicines labels?: A qualitative study.

Authors:  Mona Garada; Andrew J McLachlan; Gordon D Schiff; Elin C Lehnbom
Journal:  BMC Health Serv Res       Date:  2017-11-15       Impact factor: 2.655

Review 5.  Including the Reason for Use on Prescriptions Sent to Pharmacists: Scoping Review.

Authors:  Kathryn Mercer; Caitlin Carter; Catherine Burns; Ryan Tennant; Lisa Guirguis; Kelly Grindrod
Journal:  JMIR Hum Factors       Date:  2021-11-25

6.  Medication-Related Problems and Interventions Identified and Addressed by Pharmacists Conducting Enhanced Medication Therapy Management Services.

Authors:  Laura E Knockel; Yury Kim; Kelly Kent; William R Doucette
Journal:  Pharmacy (Basel)       Date:  2022-09-04

7.  Systematic review and meta-analysis of community pharmacy error rates in the USA: 1993-2015.

Authors:  Patrick J Campbell; Mira Patel; Jennifer R Martin; Ana L Hincapie; David Rhys Axon; Terri L Warholak; Marion Slack
Journal:  BMJ Open Qual       Date:  2018-10-02

8.  Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients.

Authors:  Rianne A Weersink; Marianna Abadier; Anthonius de Boer; Katja Taxis; Sander D Borgsteede
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.